Cantuzumab ravtansine explained

Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4).[1] It uses a more hindered disulfide linkage than cantuzumab mertansine.[2]

See also

Notes and References

  1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 . WHO Drug Information . 25 . 2 . 2011 . https://web.archive.org/web/20120401103157/http://whqlibdoc.who.int/druginfo/25_2_2011_INN105.pdf . dead . April 1, 2012 .
  2. Book: Goldmacher VS, Singh R, Chittenden T, Kovtun Y . Linker technology and impact of linker design on ADC properties. . https://books.google.com/books?id=WQgaB6VJq_4C&dq=cantuzumab+ravtansine&pg=PA131 . Phillips GL . Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications . 2013 . Springer . New York . 978-1-4614-5456-4 . 117–135 (131) .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cantuzumab ravtansine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.